Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Nasdaq

Atea Pharmaceuticals Advances HCV Treatment with Ongoing Phase 3 C-BEYOND Trial and Promising Phase 2 Results for Bemnifosbuvir and Ruzasvir at EASL 2025

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...
Healio

More frequent HCV testing among people who inject drugs may provide ‘very high value’

Please provide your email address to receive an email when new articles are posted on . More frequent HCV testing was cost-effective among people who inject drugs in both high- and low-transmission ...
Infectious Disease Advisor

Universal Pediatric HCV Screening May Be Cost-Effective

Universal hepatitis C virus screening was cost-effective compared with risk-based testing in pediatric populations.
koaa

Colorado Springs Housing Authority pauses Section 8 (HCV) assistance

COLORADO SPRINGS — The Executive Director for the Colorado Springs Housing Authority (CSHA) says funding constraints have led to them pausing Section 8, or Housing Choice Voucher (HCV), assistance.